Compare SON & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SON | CRNX |
|---|---|---|
| Founded | 1899 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 3.9B |
| IPO Year | 2014 | 2018 |
| Metric | SON | CRNX |
|---|---|---|
| Price | $50.37 | $35.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 9 |
| Target Price | $63.00 | ★ $74.78 |
| AVG Volume (30 Days) | 768.2K | ★ 903.6K |
| Earning Date | 04-21-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.09% | N/A |
| EPS Growth | ★ 510.30 | N/A |
| EPS | ★ 10.07 | N/A |
| Revenue | ★ $7,518,753,000.00 | $1,039,000.00 |
| Revenue This Year | $0.03 | $722.66 |
| Revenue Next Year | $2.01 | $183.79 |
| P/E Ratio | $5.15 | ★ N/A |
| Revenue Growth | ★ 41.72 | N/A |
| 52 Week Low | $38.65 | $24.10 |
| 52 Week High | $58.44 | $57.99 |
| Indicator | SON | CRNX |
|---|---|---|
| Relative Strength Index (RSI) | 34.55 | 26.12 |
| Support Level | $43.24 | $33.23 |
| Resistance Level | $55.00 | $37.23 |
| Average True Range (ATR) | 1.37 | 1.50 |
| MACD | -0.62 | -0.01 |
| Stochastic Oscillator | 0.00 | 3.41 |
Over its 100-year-plus history, Sonoco Products has steadily assembled a diverse portfolio of industrial and consumer packaging product offerings such as flexible and rigid plastics, reels and spools, pallets, and composite cans. The company serves a variety of consumer and industrial end markets throughout North America. Sonoco has raised its dividend each year for more than 40 years.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.